US · Healthcare · Medical Devices
EPS came in at 0.73 against a street estimate of 0.66 — a beat of 10.6%.
Analysts rate DexCom Inc a strong buy (26 buy, 3 hold, 0 sell out of 29) with an average price target of $98.15.
CONFIDENT Dexcom delivered strong Q3 growth, share gains, higher margins and record new starts, while raising operating-profit and EBITDA margin guidance and maintaining its long-term outlook. Q3 FY26 U.S. share gains and strong new starts contrasted with temporarily slower international growth caused by reimbursement timing comparisons. Analysts focused on pricing, competition, PBM access, CMS coverage, G7 15-day adoption, Ireland costs and 2027 growth. Management emphasized stable pricing, limited PBM financial exposure, strong clinical evidence and continued long-term confidence. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.25% |
| Vanguard Capital Management, LLC | 6.76% |
| Vanguard Portfolio Management, LLC | 5.27% |
| State Street Corp | 4.93% |
| Amvescap Plc. | 4.10% |
| Baillie Gifford & Co Limited. | 3.97% |
| Geode Capital Management, LLC | 3.33% |
| AllianceBernstein L.P. | 3.14% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $1,344.5 million, up from $1,209.3 million in Q3 2025. • Nine-month revenue was $3,844.8 million, | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue rose 11% year over year to $1.344 billion, compared with $1.209 billion in the third quarter of 2025. | 2026-10-29 |
| Board / officer change · Q3 2026 DEXCOM, INC. (DXCM) - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Jereme Sylvain promoted from EVP, Chief Financial Officer to EVP, Chief Opera | 2026-09-14 |
| Board / officer change · Q3 2026 DEXCOM, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Dexcom announced the appointment of Glenn S. Boehnlein as a new director, effective | 2026-09-10 |
| Quarterly report · Q2 2026 DEXCOM, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $1,308.4 million (up 13.1% vs Q2 2025: $1,157.1 million) • H1 2026 Revenue: | 2026-07-30 |
| Results announced · Q3 2026 DEXCOM Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $1.308 billion, up 13% year-over-year (12% organic) • U.S. Revenue: $93 | 2026-07-30 |
| Shareholder vote results · Q2 2026 DEXCOM, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 27, 2026 • 385,872,977 total shares outstanding as of April 1, 2026 (reco | 2026-05-28 |
| Reg FD disclosure · Q2 2026 DEXCOM, INC. (DXCM) - FORM 8-K SUMMARY HEADLINE NUMBERS • 2030 Organic Revenue Growth Target: 10%+ annually through 2030 • 2030 Non-GAAP Gross Profi | 2026-05-15 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorized a share repurchase program of up to $1 billion through December 2027 Dexcom’s board approved a share repurchase program allowing the company to buy back up to $1.0 billion of its common stock by December 31, 2027. Purchases may occur in the open market, priva | 2026-10-29 |
| Board authorizes $1.0 billion share repurchase program through June 2027 On May 14, 2026, Dexcom's Board of Directors approved a $1 billion share repurchase program, effective through June 30, 2027. This replaces the previous repurchase program, which had $250 mi | 2026-05-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for DexCom Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.